Linked Life Data

20713962

Source:http://linkedlifedata.com/resource/pubmed/id/20713962

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20713962rdf:typepubmed:Citationlld:pubmed
pubmed-article:20713962lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:20713962lifeskim:mentionsumls-concept:C0521324lld:lifeskim
pubmed-article:20713962lifeskim:mentionsumls-concept:C0442045lld:lifeskim
pubmed-article:20713962lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:20713962lifeskim:mentionsumls-concept:C1961835lld:lifeskim
pubmed-article:20713962lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:20713962lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:20713962lifeskim:mentionsumls-concept:C1280464lld:lifeskim
pubmed-article:20713962lifeskim:mentionsumls-concept:C0144544lld:lifeskim
pubmed-article:20713962lifeskim:mentionsumls-concept:C1999530lld:lifeskim
pubmed-article:20713962pubmed:issue20lld:pubmed
pubmed-article:20713962pubmed:dateCreated2010-11-22lld:pubmed
pubmed-article:20713962pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20713962pubmed:abstractTextEliglustat tartrate is an investigational oral substrate reduction therapy for Gaucher disease type 1 that is pharmacologically distinct from intravenous enzyme replacement therapy. Eliglustat tartrate improved clinical manifestations in patients who received 50 or 100 mg twice daily for 1 year during an open-label phase 2 study (Blood. 2010;116(6):893-899). We report further improvements after 2 years of treatment in 20 patients (11 females, 9 males; mean age, 33 years) with baseline splenomegaly and thrombocytopenia and/or anemia. Statistically significant (P < .001) percentage improvements from baseline occurred in platelet count (mean ± SD, 81% ± 56%), hemoglobin level (20% ± 15%), spleen volume (-52% ± 11%), and liver volume (-24% ± 13%). Mean platelet count increased ? 50 000/mm(3). Mean hemoglobin level increased 2.1 g/dL overall and 3.1 g/dL in 10 patients with baseline anemia. Organ volume reductions were greatest in patients with severe baseline organomegaly. Seventeen (85%) patients met established therapeutic goals for ? 3 of the 4 parameters. Lumbar spine bone mineral density increased 7.8% ± 10.6% (P = .01) and T-score 0.6 ± 0.8 (P = .012), with major gains in osteoporotic and osteopenic patients. Magnetic resonance imaging assessment showed that bone marrow infiltration by Gaucher cells was decreased (8/18 patients) or stable (10/18 patients). No safety-related trends emerged during 2 years of treatment. This multisite, open-label, single-arm phase 2 study is registered at www.clinicaltrials.gov as NCT00358150.lld:pubmed
pubmed-article:20713962pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20713962pubmed:languageenglld:pubmed
pubmed-article:20713962pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20713962pubmed:citationSubsetAIMlld:pubmed
pubmed-article:20713962pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20713962pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20713962pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20713962pubmed:statusMEDLINElld:pubmed
pubmed-article:20713962pubmed:monthNovlld:pubmed
pubmed-article:20713962pubmed:issn1528-0020lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:PastoresGrego...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:WatmanNoraNlld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:PeterschmittM...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:RosenbaumHann...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:RosenthalDani...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:KamathRavi...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:DragoskyMarta...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:PugaAna...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:PhillipsMiciMlld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:LukinaElenaElld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:ArreguinElsa...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:IastrebnerMar...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:KaperMathilde...lld:pubmed
pubmed-article:20713962pubmed:authorpubmed-author:SinghTejdipTlld:pubmed
pubmed-article:20713962pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20713962pubmed:day18lld:pubmed
pubmed-article:20713962pubmed:volume116lld:pubmed
pubmed-article:20713962pubmed:ownerNLMlld:pubmed
pubmed-article:20713962pubmed:authorsCompleteYlld:pubmed
pubmed-article:20713962pubmed:pagination4095-8lld:pubmed
pubmed-article:20713962pubmed:dateRevised2011-7-8lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:meshHeadingpubmed-meshheading:20713962...lld:pubmed
pubmed-article:20713962pubmed:year2010lld:pubmed
pubmed-article:20713962pubmed:articleTitleImprovement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study.lld:pubmed
pubmed-article:20713962pubmed:affiliationHematology Research Center, Russian Academy of Medical Sciences, Moscow, Russia;lld:pubmed
pubmed-article:20713962pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20713962pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:20713962pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20713962lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20713962lld:pubmed